Neovascular AMD: Unpacking Surgical Disease Management Options

Carmen A. Puliafito, MD, MBA

Director
Retina Synthesis

David A. Eichenbaum, MD, FAAO

Collaborative Associate Professor
Department of Ophthalmology
University of South Florida

Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida

Daniel M. Miller, MD, PhD

Division Medical Director, Ohio Region, Eyecare Partners
Partner, Cincinnati Eye Institute, CVP Physicians
Associate Professor Of Ophthalmology
University of Cincinnati College of Medicine

Charles C. Wykoff, MD, PhD

Retina Consultants of Texas
Retina Consultants of America
Houston Methodist Hospital
Blanton Eye Institute

Houston, TX

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Carmen A. Puliafito, MD, MBA, has had no financial relationships with ineligible companies.

David A. Eichenbaum, MD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera, Allergan, Apellis, Bausch + Lomb, Dutch Ophthalmic, EyePoint Pharmaceuticals, Genentech, Gyroscope, Iveric Bio, Kodiak, Novartis, RecensMedical, and Regeneron; Employee: Allergan; Founder: Network Eye; Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu Kanghong Biotechnology, EyePoint Pharmaceuticals, Gemini, Genentech, Gyroscope, Ionis, Iveric Bio, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Ophthea, RecensMedical, Regeneron, and Regenxbio; Speaker’s Bureau: Allergan, Apellis, Bayer, Dutch Ophthalmic, EyePoint Pharmaceuticals, Gemini, Genentech, and Novartis; Stock/Shareholder: Boston Image Reading Center, Clearside, Hemera, Network Eye, and US Retina.

Daniel M. Miller, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera, Genentech, Novartis, Regeneron, and Regenxbio; Grant/Research Support: AGTC, Alimera, Allergan, Genentech, Gyroscope, Iveric, Novartis, Regeneron, and Regenxbio; Speaker’s Bureau: Genentech. Stock/Shareholder: Vortex Surgical.

Charles C. Wykoff, MD, PhD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Aerie Pharmaceuticals, AGTC, Alimera Sciences, Allergan, Allgenesis, Alnylam, Annexon, Apellis Pharmaceutcals, Arrowhead, Bausch + Lomb, Bayer, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Cholgene, Clearside Biomedical, Curacle, EyePoint Pharmaceuticals, Foresite, Frontera, Genentech, Gyroscope, IACTA, Iveric Bio, Janssen, Kato, Kiora, Kodiak Sciences, Kriya, Merck, Nanoscope, NGM Biopharmaceuticals, Notal Vision, Novartis, OccuRx, Ocular Therapeutix, OcuTerra, OliX, ONL, Opthea, Palatin, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, Regenxbio, Resonance, Roche, Stealth, Surrozen, Théa Pharma, TissueGen, Valo, Verana, and Vitranu. Grant/Research Support: 4DMT, Adverum Biotechnologies, Aerie Pharmaceuticals, AffaMed, Aldeyra, Alexion, Alimera Sciences, Alkahest, Allergan, Amgen, Annexon, Apellis Pharmaceuticals, AsclepiX Therapeutics, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS, iRENIX, Iveric Bio, Kodiak Sciences, LMRI, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocuphire Pharma, Opthea, Oxurion, Oyster Point Pharma, RecensMedical, Regeneron, Regenxbio, Roche, SamChunDang Pharm, Sandoz, Taiwan Liposome Company, UNITY, Verily, and Xbrane. Stock/Shareholder: ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, and Vitranu.

The Evolve Medical Education staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.